在12、13或19月龄接种单剂甲型肝炎疫苗三年后的免疫记忆评估
研究评估三种单剂甲肝疫苗接种程序后的免疫记忆。儿童分别于12月龄接种Twinrix®Junior、13月龄或19月龄接种Vaqta®儿科剂型,三年后给予挑战剂量。初免三年后血清阳性率Twinrix12组为40.2%,低于Vaqta13组的65.6%和Vaqta19组的77.6%;挑战后一个月三组回忆应答比例高且相似。
要点
- 初免三年后血清阳性率Twinrix12组40.2% vs Vaqta13组65.6% vs Vaqta19组77.6%。
- 挑战剂量后一个月回忆应答比例Twinrix12组97.5%、Vaqta13组98.4%、Vaqta19组96.1%。
- 单剂甲肝疫苗在三程序均诱导强免疫应答,但需进一步研究确认长期持久性和人群影响。
核心结论
- 单剂甲型肝炎疫苗接种在三种程序下均诱导了强免疫应答。
- 需进一步研究以确认长期持久性和人群影响。
研究设计与样本
- 儿童按三种程序之一接种单剂甲肝疫苗:12月龄接种Twinrix®Junior(Twinrix12)、13月龄接种Vaqta®儿科剂型(Vaqta13)或19月龄接种Vaqta®儿科剂型(Vaqta19),三年后给予Twinrix®Junior挑战剂量。
- 在挑战剂量前和挑战后一个月采集血样,共320名儿童纳入分析。
主要发现
- 初免三年后血清阳性(≥20 mIU/mL)比例Twinrix12组为40.2%,低于Vaqta13组的65.6%和Vaqta19组的77.6%。
- 挑战剂量后一个月,回忆应答比例三组均高且相似:Twinrix12组97.5%、Vaqta13组98.4%、Vaqta19组96.1%。
关键数值与推荐
- 血清阳性定义为≥20 mIU/mL。
- 初免三年后血清阳性率:Twinrix12组40.2% vs Vaqta13组65.6% vs Vaqta19组77.6%。
- 挑战后一个月回忆应答比例:Twinrix12组97.5% vs Vaqta13组98.4% vs Vaqta19组96.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究以确认长期持久性和人群影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We aimed to evaluate immunological memory after three different single-dose hepatitis A vaccination schedules. METHODS: Children were vaccinated using one of three schedules: 1) Twinrix®Junior at 12 months (Twinrix12); 2) Vaqta®pediatric at 13 months (Vaqta13); or 3) Vaqta®pediatric at 19 months of age (Vaqta19), followed by a challenge dose with Twinrix®Junior three years later. Blood samples were collected before and one month post-challenge dose. RESULTS: A total of 320 children were included in this analysis. Seropositivity (≥20 mIU/mL) three years post-primary vaccination was lower for the Twinrix12 schedule (40.2 %) compared to the Vaqta13 (65.6 %) or Vaqta19 schedules (77.6 %). One month post-challenge dose, the proportion of participants with an anamnestic response was high and similar across the three schedules (Twinrix12: 97.5 %; Vaqta13: 98.4 %; Vaqta19: 96.1 %). CONCLUSION: Single-dose hepatitis A vaccination induced a strong immune response across the three schedules. However, further studies are needed to confirm long-term durability and population impact.
引用
- Febriani Y, Ursu MM, Sauvageau C, et al. Immune memory assessment three years following a single dose of hepatitis a vaccine at 12, 13 or 19 months of age. Vaccine. 2025. PMID: 41453243. doi:10.1016/j.vaccine.2025.128144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。